Aby J. Mathew - Apr 12, 2022 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
EVP & Chief Scientific Officer
Signature
/s/ Aby J. Mathew
Stock symbol
BLFS
Transactions as of
Apr 12, 2022
Transactions value $
$0
Form type
4
Date filed
4/13/2022, 09:24 PM
Previous filing
Mar 31, 2022
Next filing
Apr 19, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise +45.7K +20.28% 271K Apr 12, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Restricted Stock Award Options Exercise $0 -45.7K -100% $0.00* 0 Apr 12, 2022 Common Stock 45.7K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).